The iLet Bionic Pancreas is an automated insulin delivery (AID) system. It connects with a continuous glucose monitor (CGM) to determine insulin dosing and adapt insulin delivery based on changing needs. Because it requires less data input and manual programming than other AID devices, it may reduce the burden of daily diabetes management. The iLet Bionic Pancreas is FDA-approved for people with Type 1 diabetes.

Status

A study is currently underway to evaluate the safety and effectiveness of using the insulin-only Bionic Pancreas system compared to using one’s usual insulin delivery method. The study is for people at least 14 years old with a clinical diagnosis of cystic fibrosis-related diabetes (CFRD).

Sponsor

This program is sponsored by the Cystic Fibrosis Foundation and is being conducted within the Therapeutics Development Network (TDN).